Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro
- PMID: 2124308
- DOI: 10.1007/BF01649034
Anti-mistletoe lectin antibodies are produced in patients during therapy with an aqueous mistletoe extract derived from Viscum album L. and neutralize lectin-induced cytotoxicity in vitro
Abstract
The humoral response components of an aqueous mistletoe extract (HM) was evaluated in 23 tumor patients who had been treated from 2 months up to 6 years with increasing dosages of HM. IgG antibodies against mistletoe lectin and other components of this extract were detected by ELISA, immunodiffusion, and blotting technique, using either the aqueous extract (HM) or a purified lectin preparation (ML). Their activity depended upon dosage of HM and length of therapy. No anti-HM/ML antibodies of the IgM type could be detected. Immunoblotting revealed lectin-specific antigens at 62 kD, 33k D, and 29 kD. In the presence of ML or HM, PHA-induced proliferation of normal lymphocytes was decreased in a dose-dependent manner; this effect was neutralized by adding the IgG fraction from pooled anti-HM-antibody-positive sera, indicating that the cytotoxic effect of lectins was eliminated by these specific antibodies. In view of these findings, it is questionable whether exposing tumor cells to mistletoe extracts in vivo exerts the same direct effect on tumor cells that is observed in vitro.
Similar articles
-
Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.).Klin Wochenschr. 1991 Jun 18;69(9):397-403. doi: 10.1007/BF01647413. Klin Wochenschr. 1991. PMID: 1921242
-
Induction of anti-mistletoe lectin antibodies in relation to different mistletoe-extracts.Anticancer Drugs. 1997 Apr;8 Suppl 1:S57-9. doi: 10.1097/00001813-199704001-00013. Anticancer Drugs. 1997. PMID: 9179370 Review.
-
In vivo-induction of antibodies to mistletoe lectin-1 and viscotoxin by exposure to aqueous mistletoe extracts: a randomised double-blinded placebo controlled phase I study in healthy individuals.Eur J Med Res. 2002 Apr 30;7(4):155-63. Eur J Med Res. 2002. PMID: 12010650 Clinical Trial.
-
Comparison of the effects of Viscum album lectin ML-1 and fresh plant extract (Isorel) on the cell growth in vitro and tumorigenicity of melanoma B16F10.Cancer Biother Radiopharm. 1998 Apr;13(2):121-31. doi: 10.1089/cbr.1998.13.121. Cancer Biother Radiopharm. 1998. PMID: 10850348
-
Modulation of cytotoxicity and enhancement of cytokine release induced by Viscum album L. extracts or mistletoe lectins.Anticancer Drugs. 1997 Apr;8 Suppl 1:S3-8. doi: 10.1097/00001813-199704001-00002. Anticancer Drugs. 1997. PMID: 9179359 Review.
Cited by
-
Differential Effects of Viscum album Preparations on the Maturation and Activation of Human Dendritic Cells and CD4⁺ T Cell Responses.Molecules. 2016 Jul 14;21(7):912. doi: 10.3390/molecules21070912. Molecules. 2016. PMID: 27428940 Free PMC article.
-
NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors.Evid Based Complement Alternat Med. 2013;2013:964592. doi: 10.1155/2013/964592. Epub 2013 Oct 27. Evid Based Complement Alternat Med. 2013. PMID: 24285980 Free PMC article.
-
Effect of a mistletoe extract (Iscador QuFrF) on viability and migratory behavior of human peripheral CD4+ and CD8+ T lymphocytes in three-dimensional collagen lattices.In Vitro Cell Dev Biol Anim. 1997 Oct;33(9):710-6. doi: 10.1007/s11626-997-0129-8. In Vitro Cell Dev Biol Anim. 1997. PMID: 9358287
-
Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.).Klin Wochenschr. 1991 Jun 18;69(9):397-403. doi: 10.1007/BF01647413. Klin Wochenschr. 1991. PMID: 1921242
-
Adjuvant Therapy Using Mistletoe Containing Drugs Boosts the T-Cell-Mediated Killing of Glioma Cells and Prolongs the Survival of Glioma Bearing Mice.Evid Based Complement Alternat Med. 2018 Aug 27;2018:3928572. doi: 10.1155/2018/3928572. eCollection 2018. Evid Based Complement Alternat Med. 2018. PMID: 30224928 Free PMC article.